Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9332613 | 0.83 | GAA (0.53) | KDM4EGAAESR1ESR2MEN1 | |
| SCHEMBL31612188 | 0.82 | ERN1 (0.69) | ERN1SRC | |
| SCHEMBL210156 | 0.82 | ERN1 (0.69) | ERN1SRC | |
| SCHEMBL8653490 | 0.81 | KDM4E (0.44) | ERN1KDM4EGAAMEN1KMT2A | |
| SCHEMBL1002848 | 0.81 | KDM4E (0.59) | ERN1KDM4EGAAESR1ESR2 | |
| SCHEMBL38650748 | 0.80 | ERN1 (0.67) | ERN1KDM4ESRCMEN1KMT2A | |
| SCHEMBL11650048 | 0.80 | ERN1 (0.67) | ERN1KDM4ESRCMEN1KMT2A | |
| SCHEMBL5882146 | 0.80 | KDM4E (0.48) | ERN1KDM4EGAAMEN1KMT2A | |
| SCHEMBL15557442 | 0.79 | ERN1 (0.55) | ERN1KDM4EGABRA1GABRB2POLB | |
| SCHEMBL29422738 | 0.79 | ERN1 (0.55) | ERN1KDM4EGABRA1GABRB2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9622993-B2 | Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170027893-A1 | THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-7071212-B2 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027893-A1 | THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF | BRAF, PLAAT3, PLAAT2 | ERN1 3381/4885KDM4E 1346/4885GAA 2166/4885 |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ERN1 1281/4885KDM4E 1998/4885GAA 1949/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ERN1 1281/4885KDM4E 1998/4885GAA 1949/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ERN1 1281/4885KDM4E 1998/4885GAA 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.